This is a preview of subscription content, access via your institution
Subscribe to Journal
Get full journal access for 1 year
only $9.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Greenberg PL, Cox C, LeMeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J . International scoring system for evaluating prognosis in myelodysplastic syndromes Blood 1997 89: 2079–2088
Aul C, Gattermann N, Schneider W . Age-related incidence and other epidemiological aspects of myelodysplastic syndrome Br J Haematol 1994 87: 743–745
De Witte T, Suciu S, Peetermans M, Fenaux P, Strijckmans P, Hayat M, Jaksic B, Selleslag D, Zittoun R, Dardenne M, Solbou G, Zwierzina H, Muus P . Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute leukemia following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of European Organization for Research and Treatment in Cancer (EORTC-LCG) Leukemia 1995 9: 1805–1811
Gassmann W, Schmitz N, Loffler H, De Witte T . Intensive chemotherapy and bone marrow transplantation for myelodysplastic syndromes Semin Hematol 1996 33: 196–205
Yaguchi M, Miyazawa K, Katagiri T, Nishimaki J, Kizaki M, Tohyama K, Toyama K . Vitamin K2 and its derivatives induce apoptosis in leukemia cells and enhance the effect of all-trans retinoic acid Leukemia 1997 11: 779–787
Yaguchi M, Miyazawa K, Otawa M, Katagiri T, Nishimaki J, Uchida Y, Iwase O, Gotoh A, Kawanishi Y, Toyama K . Vitamin K2 selectively induces apoptosis of blastic cells in myelodysplastic syndrome: flow cytometric detection of apoptosis cells using APO2.7 monoclonal antibody Leukemia 1998 12: 1392–1397
Sasaki I, Hashimoto S, Yoda M, Hida T, Ohsawa S, Nakajo S, Nakayama K . Novel role of vitamin K2: a potent inducer of differentiation of various human myeloid leukemia cell lines Biochem Biophys Res Commun 1994 205: 1305–1310
Takami A, Nakao S, Ontachi Y, Yamauchi H, Matsuda T . Successful therapy of myelodysplastic syndrome with menatetrenone, a vitamin K2 analog Int J Hematol 1999 69: 24–26
Yaguchi M, Miyazawa K, Otawa M, Ito Y, Kawanishi Y, Toyama K . Vitamin K2 therapy for a patient with myelodysplastic syndrome Leukemia 1999 13: 144–145
Orimo H, Shiraki M, Tomita A, Morri H, Fujita T, Ohata M . Effects of menatetrenone on the bone and calcium metabolism in osteoporosis: a double-blind placebo-controlled study J Bone Miner Metab 1998 16: 106–112
This study was supported by Health Science Research Grants to Research Committee for Idiopathic Hemopoietic Disorders of the Ministry of Health and Welfare in Japan.
About this article
Cite this article
Miyazawa, K., Nishimaki, J., Ohyashiki, K. et al. Vitamin K2 therapy for myelodysplastic syndromes (MDS) and post-MDS acute myeloid leukemia: information through a questionnaire survey of multi-center pilot studies in Japan. Leukemia 14, 1156–1157 (2000). https://doi.org/10.1038/sj.leu.2401790
This article is cited by
Menatetrenone facilitates hematopoietic cell generation in a manner that is dependent on human bone marrow mesenchymal stromal/stem cells
International Journal of Hematology (2020)
Vitamin K homologs as potential biomarkers for disease activity in patients with rheumatoid arthritis
Journal of Bone and Mineral Metabolism (2017)
Journal of Cancer Research and Clinical Oncology (2011)
Combination of 22-oxa-1,25-dihydroxyvitamin D3, a vitamin D3 derivative, with vitamin K2 (VK2) synergistically enhances cell differentiation but suppresses VK2-inducing apoptosis in HL-60 cells
Apoptosis/differentiation-inducing effects of vitamin K2 on HL-60 cells: dichotomous nature of vitamin K2 in leukemia cells